



03-18-04

[Handwritten signature]

Express Mail Label No.	Dated: _____
------------------------	--------------

Docket No.: 02755/100J524-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bruce E. Reidenberg et al.

Application No.: 10,173,049

Confirmation No.:

Filed: December 15, 2003

Art Unit: N/A

For: TRANSDERMAL BUPRENORPHINE TO
TREAT PAIN IN SICKLE CELL CRISIS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each document on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information

Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: March 16, 2004

Respectfully submitted,

By 
Anna Löqvist, Ph.D.

Limited Recognition Under
37 C.F.R. 10.9(b) (see attached)
Representative of Applicants
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 753-6237 (Fax)



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	101/736,049
				Filing Date	December 15, 2003
				First Named Inventor	Bruce E. Reidenberg
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	02755/100J524-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-4,806,341	02-21-1989	Chien et al.	
	2	US-5,026,556	06-25-1991	Drust et al.	
	3	US-5,069,909	12-03-1991	Sharma et al.	
	4	US-5,225,199	07-06-1993	Hidaka et al.	
	5	US-5,240,711	08-31-1993	Hille et al.	
	6	US-5,613,958	03-25-1997	Kochinke et al.	
	7	US-5,968,547	10-19-1999	Reder et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	8	Adrianensen et al., Acta Anaesthesiol Belg 1985;36:33-40	
	9	Brema et al., Int J Clin Pharmacol Res 1996;16:109-116	
	10	Capogna et al., Anaesthesia 1988, 43:128-130	
	11	Hale et al., Abstract, 08 GSA 2001	
	12	Hale et al., Abstract, Nat'l Clin. Symposium of the American College of Nurse Practitioners; Oct. 2001	
	13	Hale et al., J. Clin. Pharmacol. 2001; 41(9):1027, Abstract 58	
	14	Inagaki et al., Anesth Analg 1996;83:530-536	
	15	Nasar et al., Curr Med Res Opin 1986;10:251-255	
	16	Oda et al., Br. J. Anaesthesia 1999;82(6):900-903	
	17	Reidenberg et al., J. Clin. Pharmacol. 2001;41(9):1027, Abstract 57	
	18	Spyker et al., J. Amer. Geriatrics Soc. 2002;50(4):S66, Abstract P162	
	19	Spyker et al., J. Pain 2002;3(2, Suppl. 1):12, Abstract 645	
	20	Spyker et al., J. Pain 2002;3(2, Suppl. 1):14, Abstract 653	
	21	Spyker et al., Clin. Pharmacol. Ther. 2000;67(2):145, Abstract PIII-12	
	22	Spyker et al., Clin. Pharmacol. Ther. 2001;69(2):P33, Abstract PII-3	
	23	Spyker et al., Conference Abstract presented on October 15, 2001	
	24	Tauzin-Fin et al., Eur J Anaesthesiol 1998;15:147-152	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------